News

The conversation centers around the pursuit of effective neuroprotective agents in stroke, the challenges of clinical trial design, and what could make future therapies succeed. [WATCH TIME: 5 minutes]

James N. Brenton, MD, director of the Pediatric MS and Related Disorders Clinic at the University of Virginia, discussed how lifestyle modification and multidisciplinary care can support disease management in children with multiple sclerosis.

At CNS 2025, the program director of child neurology residency at Boston's Children's Hospital discussed strategies to expose medical students to child neurology early in their clinical training. [WATCH TIME: 4 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.

In episode 2, a pair of stroke neurologists explore how artificial intelligence is accelerating stroke detection, streamlining workflows, and redefining collaboration in modern stroke care. [WATCH TIME: 4 minutes]

New findings reveal early treatment with Trappsol Cyclo shows promise for young patients with Niemann-Pick disease type C1, enhancing safety and efficacy.

The president and founder of the Stuttering Treatment and Research Society highlighted the significance of interdisciplinary care for both children and adults with stuttering. [WATCH TIME: 5 minutes]

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

A recent review of studies over the past decade, presented at CNS 2025, suggests that the ketogenic diet can significantly reduce seizure frequency in children with drug-resistant epilepsy.

In this kickoff episode, Drs. Brian Snelling, MD, and Felipe De Los Rios, MD, discussed how evolving evidence continues to expand mechanical thrombectomy eligibility, from extended time windows to large-core and medium-vessel occlusions. [WATCH TIME: 6 minutes]

A new study reported that children and adolescents with Tourette syndrome on dopamine D2 receptor antagonists had higher rates of psychiatric and metabolic adverse events than those unexposed.

The codirector of interventional neuroradiology at Baptist Health's Neuroscience Institute, outlined a pragmatic, anatomy-first approach to aneurysm care, balancing endovascular options against open surgery and ways to tailor decision-making. [WATCH TIME: 3 minutes]

Beth McQuiston, MD, neurologist and medical director in Abbott’s diagnostics business, discussed the clinical value of Abbott’s FDA-cleared i-STAT TBI test as it was named to TIME’S 2025 Best Inventions List.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai talked about the major biomarkers used to track progression in Huntington disease. [WATCH TIME: 5 minutes]

Leigh Charvet, PhD, professor of neurology at NYU Grossman School of Medicine, provided clinical insights to her team’s pilot study using at-home brain stimulation to reduce cannabis use in women with multiple sclerosis.

The executive vice president and head of R&D at Lundbeck provided more context on the scientific rationale of amlenetug, an investigational monoclonal antibody designed to halt the spread of alpha-synuclein aggregates in multiple system atrophy. [WATCH TIME: 3 minutes]

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.

At MDS 2025, the senior medical director of UCB's Translational Medicine Neuroscience and Gene Therapy presented data from the ATLANTIS study of glovadalen in patients with Parkinson disease. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Researchers recently received a $2.8 million 3-year grant to develop next-generation implantable responsive neurostimulation devices for patients with epilepsy.

The associate professor of neurology and pediatrics at the University of California, San Francisco, discussed updated recommendations for continuous EEG use in neonates, highlighting risk stratification, and the growing importance of family involvement. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on deep brain stimulation for Parkinson disease.

An interim analysis from TEMPO-4, presented as a late-breaker at MDS 2025, showed that tavapadon showed sustained long-term safety in Parkinson disease.

Neurology News Network. for the week ending October 18, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 17, 2025.

A phase 3 trial presented at the 2025 MDS Congress suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

The co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.